Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3913917 | 0.89 | ADRB2 (0.49) | ADRB2ADRB1LMNACYP3A4CYP2C9 | |
| SCHEMBL3924377 | 0.89 | ADRB2 (0.44) | ADRB2ADRB1LMNACYP3A4CYP2C9 | |
| SCHEMBL5665460 | 0.88 | ADRB2 (0.45) | ADRB2ADRB1LMNACYP3A4CYP2C9 | |
| SCHEMBL3914058 | 0.88 | ADRB2 (0.45) | ADRB2ADRB1LMNACYP3A4CYP2C9 | |
| SCHEMBL3913331 | 0.87 | ADRB2 (0.47) | ADRB2ADRB1LMNACYP3A4CYP2C9 | |
| SCHEMBL3913912 | 0.87 | ADRB2 (0.47) | ADRB2ADRB1LMNACYP3A4CYP2C9 | |
| SCHEMBL3992464 | 0.87 | ADRB2 (0.49) | ADRB2ADRB1LMNACYP3A4CYP2C9 | |
| SCHEMBL3923032 | 0.86 | ADRB2 (0.47) | ADRB2ADRB1LMNACYP3A4CYP2C9 | |
| SCHEMBL3912467 | 0.86 | ADRB2 (0.47) | ADRB2ADRB1LMNACYP3A4CYP2C9 | |
| SCHEMBL3918574 | 0.85 | ADRB2 (0.46) | ADRB2ADRB1LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730141-B1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2009-05-27 | — | — | EP | claimed |
| EP-1730141-B1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2009-05-27 | — | — | EP | disclosed |
| US-7538141-B2 | Compounds for the treatment of diseases | PFIZER INC. | 2009-05-26 | — | — | US | disclosed |
| US-20050222128-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222128-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, CYP11B2 | ADRB2 639/4885ADRB1 569/4885LMNA 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.